Most women who ask us about GLP-1 medications describe the same thing first, and it is rarely a number on a scale.
It is the noise. Thinking about the next meal during the current one. Negotiating with yourself at four in the afternoon. Deciding, again. If you have spent years assuming that background hum is a discipline problem, the most useful thing we can tell you is that it is a signaling problem, and it is the thing these medications act on most directly.
They work with a hormone you already make
Every time you eat, your intestine releases a hormone called GLP-1. It tells your pancreas to release insulin when your glucose is high, and to ease off when it is not. It slows how quickly food leaves your stomach. And it speaks to the parts of your brain that regulate appetite.
GLP-1 medications amplify that same signal, at levels and for longer than your body produces on its own. One of them, tirzepatide, also acts on a second incretin receptor called GIP. Nothing foreign is being introduced. A system you already run is simply being turned up.
Which is why this is not a willpower story
There are GLP-1 receptors in the appetite-regulating regions of your brain, and the medication reaches them directly. When the food noise quiets, that is not discipline finally arriving after twenty years of failing to show up. It is a hormonal effect on a system that was always running in the background.
We say this plainly because so many women arrive carrying a decade of self-blame for something that was never a character trait. Putting the mechanism in front of you is often the part that lands hardest, and it is usually the most useful thing that happens in a first visit.
Why we do not start with your BMI
This is where our approach differs from most programs, and the reason is physiologic.
BMI is a ratio of weight to height. It cannot tell muscle from visceral fat, and it routinely overlooks the woman we see most often: someone whose weight sits in a perfectly normal range while her body fat percentage, her fasting insulin, and her ApoB say something else entirely. She gets told she is fine. She has been told that for years.
So we measure body composition on InBody and read it alongside your labs. Percent body fat, not BMI, is our starting point for whether this medication makes sense, together with a documented metabolic picture such as insulin resistance, prediabetes, elevated ApoB, or a history of gestational diabetes. Your BMI still gets recorded, because it determines whether a prescription falls inside FDA-approved labeling or is off-label, and you are entitled to know which one applies to you.
And why we care as much about what you keep as what you lose
Not all of the weight lost on these medications is fat. More fat than muscle comes off overall, but enough muscle can go with it that we treat it as something to actively manage rather than a footnote. For a woman already losing muscle to the menopause transition, trading it for a smaller number is a bad deal.
So protein and resistance training are part of the prescription, not advice bolted on afterward. We set a protein target, we expect strength work two to three times a week, and we repeat your body composition to confirm you are losing fat and holding muscle. If both are falling, the plan changes. That is the entire point of measuring.
What we check before we prescribe
These are effective medications, and like any effective medication they are not right for everyone. The screening is genuinely the reassuring part, so here is what it covers.
A small number of histories rule this out entirely, and we ask about them before anything else: a personal or family history of medullary thyroid cancer, or the genetic syndrome MEN2. We also do not prescribe in pregnancy or while trying to conceive, in type 1 diabetes, or alongside an active eating disorder.
Beyond that, we review your history of pancreatitis or gallbladder disease, any prior bariatric surgery or significant digestive issues, your current medications, and your mental health history. Most side effects are digestive, dose-related, and settle with slow titration. Gallbladder problems and pancreatitis are less common but serious, and we tell you exactly which symptoms warrant a call rather than waiting it out. One practical note we make sure every patient hears: because these medications slow digestion, tell any surgeon or anesthesiologist that you are taking one.
None of this is meant to alarm you. It is meant to show you what careful looks like.
What we prescribe
We use FDA-approved GLP-1 and GIP/GLP-1 medications. We do not market compounded versions, and we would tell you directly if a compounded formulation were ever appropriate for you and why.
Which one, if either, depends on more than weight. Semaglutide carries cardiovascular outcomes evidence and approvals that tirzepatide does not yet have. Tirzepatide produces greater average weight reduction in head-to-head trials and holds an approval for obstructive sleep apnea. Matching the medication to the rest of your picture is most of the work, and it is work that requires knowing your picture.
If you have been wondering whether this is for you
The honest answer is that we cannot tell you from an article, and neither can anyone else. What we can do is measure the things that actually determine the answer, explain what we find in plain language, and tell you if the answer is no.
Book a consultation and let us look properly.
This article is general health education and is not a substitute for individualized medical advice. GLP-1 and GIP/GLP-1 medications have risks and are not appropriate for everyone; individual results vary. Whether any medication is right for you is determined during physician evaluation and screening.
